Explore

Trendline Trendline
Novo Nordisk Seeks U.S. Approval for CagriSema to Diversify Beyond Semaglutide

Novo Nordisk Seeks U.S. Approval for CagriSema to Diversify Beyond Semaglutide

Novo Nordisk Seeks U.S. Approval for CagriSema to Diversify Beyond Semaglutide
Rapid Read Rapid Read
CRISPR-Based Gene Therapy Shows Promise in Sustaining Lower Lipid Levels for a Year

CRISPR-Based Gene Therapy Shows Promise in Sustaining Lower Lipid Levels for a Year

Researchers have reported promising results from a small study involving a one-time CRISPR-based gene therapy shot that helped individuals with elevated cholesterol and triglyceride levels maintain significantly lower lipid levels for at least a year. Mel Mann, a patient advocate, highlighted this development, noting that the therapy represents a 'different model' compared to traditional treatments. The study, though small and involving severe cases, demonstrated that the highest dose of the CRISPR shot reduced LDL cholesterol and triglycerides by approximately half, with the effects sustained over the year. This suggests a potential for a durable therapeutic intervention for lipid management through gene editing.
Trendline Trendline
VedaBio Partners with UCP Merchant Medicine to Position CRISPR Molecular Diagnostics for Urgent Care Market

VedaBio Partners with UCP Merchant Medicine to Position CRISPR Molecular Diagnostics for Urgent Care Market

VedaBio Partners with UCP Merchant Medicine to Position CRISPR Molecular Diagnostics for Urgent Care Market
Rapid Read Rapid Read
Popular Supplements Like Turmeric, Lion's Mane, and Omega-3 Show Limited Clinical Benefits

Popular Supplements Like Turmeric, Lion's Mane, and Omega-3 Show Limited Clinical Benefits

Despite widespread popularity, several commonly used supplements, including turmeric, lion's mane mushrooms, and omega-3 fatty acids, are showing limited or disappointing benefits in clinical trials. Turmeric's key ingredient, curcumin, is often touted for anti-inflammatory and anti-cancer properties, but many original studies supporting these claims have been retracted due to flaws. Curcumin is also poorly soluble and largely excreted, making its efficacy questionable, and some high-bioavailability formulations have been linked to liver injury. Lion's mane mushrooms, marketed as cognitive enhancers, lack substantial research to support these claims, with experts calling for more evidence. Similarly, omega-3 supplements, despite the known benefits of fish consumption, have shown little to no effect on lifespan, heart health, or brain function in rigorous randomized trials and Cochrane reviews.
Rapid Read Rapid Read
ARPA-H Funds Teams to Advance On-Demand Genetic Medicine Manufacturing

ARPA-H Funds Teams to Advance On-Demand Genetic Medicine Manufacturing

The Advanced Research Projects Agency for Health (ARPA-H) has announced contract awards for its Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program. This initiative aims to create an automated network capable of producing individualized, ribonucleic acid (RNA)-based genetic medicines on demand. The program seeks to replace the current slow, costly, and centralized manufacturing model with one designed for speed, scale, and reach. ARPA-H plans to invest up to $125 million in this research and development program. The goal is to develop automated manufacturing and real-time quality control into a distributed biomanufacturing network, allowing treatments to be made closer to the patient. This new paradigm is expected to empower communities nationwide to affordably produce cutting-edge treatments, rather than relying solely on major biomanufacturing hubs. The program will engage the U.S. Food and Drug Administration (FDA) to co-develop the necessary regulatory framework.
Trendline Trendline
Women's Health Technology Market Faces Scrutiny Over Capacity Amidst Growing Demand

Women's Health Technology Market Faces Scrutiny Over Capacity Amidst Growing Demand

Women's Health Technology Market Faces Scrutiny Over Capacity Amidst Growing Demand
Rapid Read Rapid Read
FDA Issues Boxed Warning for Injectafer Due to Risk of Severe Hypophosphatemia

FDA Issues Boxed Warning for Injectafer Due to Risk of Severe Hypophosphatemia

The Food and Drug Administration (FDA) has mandated a boxed warning for ferric carboxymaltose injection, marketed as Injectafer, to highlight the risk of symptomatic hypophosphatemia (low phosphate levels in the blood). This is the agency's most stringent safety warning. The warning advises phosphate monitoring for patients at risk and those receiving repeat therapy within three months. Hypophosphatemia linked to Injectafer can lead to serious health issues, including hospitalization, prolonged phosphate replacement therapy, osteomalacia (bone softening), and fractures. The FDA's decision follows continued reports of symptomatic hypophosphatemia despite previous labeling updates in February 2020 and May 2023 that aimed to strengthen warnings about this risk. Data from the FDA’s Sentinel System indicates that serum phosphate testing occurs in less than 20% of Injectafer administration episodes, suggesting a gap in current monitoring practices.
Trendline Trendline
Hims Hers Expands into Australia, Marking First Asia-Pacific Market Entry

Hims Hers Expands into Australia, Marking First Asia-Pacific Market Entry

Hims Hers Expands into Australia, Marking First Asia-Pacific Market Entry
Rapid Read Rapid Read
Divalproex Sodium Linked to Severe Fatalities and Adverse Events, Including Hypothermia

Divalproex Sodium Linked to Severe Fatalities and Adverse Events, Including Hypothermia

Divalproex sodium, a medication used for seizure control, mood stabilization, and migraine prevention, has been associated with severe and potentially fatal adverse events. These include severe fatal hepatotoxicity (liver failure), acute hemorrhagic pancreatitis, and severe hyperammonemic encephalopathy, which can manifest as confusion, lethargy, and hypothermia. The risk of fatal hepatotoxicity is particularly elevated in children under two years old, especially those with congenital metabolic disorders, severe seizure disorders with mental retardation, or organic brain disease. Patients with hereditary mitochondrial disease caused by mutations in the POLG gene also face an increased risk. The medication carries a black box warning from the FDA due to these serious risks, as well as the potential for major congenital malformations and decreased IQ scores if taken during pregnancy. Regular monitoring of liver function, blood counts, and metabolic screenings is crucial before and during treatment with dival...
USA Today USA Today
Modern medicine failed her. She turned to toad venom instead

Modern medicine failed her. She turned to toad venom instead

An increasing number of people are turning to complementary and alternative medicines, and the terms are evolving. Here's what's going on.
Rapid Read Rapid Read
Northwest Naturals Recalls Pet Food Due to Salmonella and Listeria Contamination Risk

Northwest Naturals Recalls Pet Food Due to Salmonella and Listeria Contamination Risk

Northwest Naturals has issued a recall for certain pet food products due to potential contamination with salmonella and listeria bacteria. The affected products include its frozen chicken recipe, which serves as both cat food and a protein topper for dogs, sold in two-pound bags with a best-by date of January 26, 2028. Additionally, the frozen raw diet for dogs recipe, sold in six-pound bags with a best-by date of January 25, 2028, is also part of the recall. Both products were distributed and sold nationwide in various stores across the United States. As of the announcement, no illnesses in pets or humans have been reported in connection with this recall. The company is taking precautionary measures to ensure the safety of pets and their owners, advising consumers to check the FDA website for more details regarding the recall.
Rapid Read Rapid Read
FDA Approves MIMRYLO for Adults with Polycythemia Vera, Addressing Unmet Need

FDA Approves MIMRYLO for Adults with Polycythemia Vera, Addressing Unmet Need

The U.S. Food and Drug Administration (FDA) has approved MIMRYLO (rusfertide) for the treatment of adults diagnosed with polycythemia vera (PV) and erythrocytosis. This marks a significant development as MIMRYLO is the first approved therapy that functions by mimicking hepcidin, a hormone crucial for regulating iron availability and the production of red blood cells. The approval is largely based on compelling data from the Phase 3 VERIFY trial, which demonstrated substantially improved hematocrit control and a notable reduction in the need for phlebotomy procedures when compared to a placebo combined with standard care. Polycythemia vera is a chronic blood cancer characterized by an overproduction of red blood cells, leading to increased blood viscosity and a higher risk of serious cardiovascular complications such as thrombosis and stroke. The primary goal in treating PV is to maintain hematocrit levels below 45%, a challenge for many patients who often require frequent phlebotomies despite receiving sta...